Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
STAT+
Health
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
The Readout LOUD
STAT+

LISTEN: Why fatty livers are a pharma goldmine, a guide to ASCO and BIO, and Trump’s latest drug price promise

  • Damian Garde
  • Rebecca Robbins
  • Adam Feuerstein

By Damian Garde , Rebecca Robbins and Adam Feuerstein May 31, 2018

Reprints

Is the drug industry spending millions on a made-up disease? Have the latest cancer drugs been overhyped? And why does anyone go to BIO?

We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a discussion of NASH, the purported billion-dollar market opportunity that might be too good to be true, followed by a breakdown of a pair of upcoming conferences — one packed with news and the other not so much. Then comes a lightning round that touches on President Trump’s vague promises, the mystery surrounding a genomics pioneer, and drugs that make you racist.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Rebecca Robbins

Rebecca Robbins

Health Tech Correspondent

Rebecca covers health technology. She is the co-author of the newsletter STAT Health Tech.

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Tanzania reports a Marburg outbreak, Africa’s second this year
Tanzania reports a Marburg outbreak, Africa’s second this year
A new Medicare ruling could give virtual reality companies…
A new Medicare ruling could give virtual reality companies an easier path to payment
Medicaid needs to change its archaic rules for women…
Medicaid needs to change its archaic rules for women seeking permanent contraception
Study finds same small rise in breast cancer risk…
Study finds same small rise in breast cancer risk in many forms of hormonal birth control
Patient groups balk at former AstraZeneca official negotiating U.K.-India…
Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal
Altimmune’s obesity drug fails to stand out from blockbuster…
Altimmune’s obesity drug fails to stand out from blockbuster treatments in early data

Recommended Stories